Kane Biotech Signs Distribution Agreement with The Stevens Company

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Kane Biotech Signs Distribution Agreement with The Stevens CompanyAuthor of the article:Expands Kane Biotech’s commercial footprint and access to the revyve® product line across CanadaTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountWINNIPEG, Manitoba, Oct. 20, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it has signed a non-exclusive distribution agreement with The Stevens Company Limited (“Stevens”) for the resale of Kane Biotech’s Health Canada-licensed revyve® wound-care products in Canada.This advertisement has not loaded yet, but your article continues below.Under the agreement, Stevens will be authorized to purchase and resell revyve Antimicrobial Wound Gel in 1 oz and 3 oz formats and revyve Antimicrobial Wound Gel Spray in the 5 oz format throughout Canada. The agreement is effective October 1, 2026.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againThe agreement is an important step in Kane Biotech’s Canadian distribution strategy. Stevens supplies hospitals, long-term care homes and community healthcare providers across Canada and has significantly expanded its footprint through strategic acquisitions and partnerships, including Schaan Healthcare Products (SK) and CB Medical (AB) in 2024, followed by the complete integration of TRH Services Inc. in early 2026. This partnership combines Kane’s clinical expertise and relationships with Stevens’ established sales and distribution network to broaden revyve’s reach and make it easier for healthcare providers to source and adopt the products.“Partnering with Stevens brings together two organizations with strong relationships, deep market experience and a shared commitment to improving access to better wound care solutions across Canada,” said Patti Burke-Martin, Vice President of Business Development, Canada. “By combining our respective networks, expertise and reach, we can accelerate the adoption of revyve while continuing to challenge traditional approaches to wound hygiene and biofilm management with a truly differentiated and disruptive solution.”This advertisement has not loaded yet, but your article continues below.Health Canada-licensed revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel SprayThe revyve product line is designed to support wound hygiene by providing a moist wound environment conducive to healing, using antimicrobial technology to help inhibit microbial colonization and facilitating debridement through a moist wound environment.About The Stevens Company LimitedOwned and operated by six generations of the Stevens family since its original founding in London, England in 1830, The Stevens Company is a 100% Canadian-owned distributor of medical and laboratory supplies. With facilities in Vancouver, Calgary, Saskatoon, Winnipeg, Brampton, Montreal, and Halifax, Stevens provides valuable services to healthcare providers, helping them serve the needs of their patients and clients for nearly 200 years. For more information, visit stevens.ca.About Kane Biotech Inc. (TSX-V:KNE)Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada licensed. To learn more, visit https://kanebiotech.com/products.This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.Join Kane’s Distribution List & Social Media:To stay informed on the latest developments, sign up for the Company’s email distribution list.Website & Corporate Presentation:Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Caution Regarding Forward-Looking InformationThis press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.